Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A large body of evidence suggests that, besides their cholesterol-lowering effect, statins exert anti-inflammatory action. Consequently, statins may have therapeutic potential in immune-mediated disorders such as multiple sclerosis. Our objectives were to determine safety, tolerability and efficacy of low-dose atorvastatin plus high-dose interferon beta-1a in multiple sclerosis patients responding poorly to interferon beta-1a alone. Relapsing-remitting multiple sclerosis patients, aged 18-50 years, with contrast-enhanced lesions or relapses while on therapy with interferon beta-1a 44 microg (three times weekly) for 12 months, were randomized to combination therapy (interferon + atorvastatin 20 mg per day; group A) or interferon alone (group B) for 24 months. Patients underwent blood analysis and clinical assessment with the Expanded Disability Status Scale every 3 months, and brain gadolinium-enhanced magnetic resonance imaging at screening, and 12 and 24 months thereafter. Primary outcome measure was contrast-enhanced lesion number. Secondary outcome measures were number of relapses, EDSS variation and safety laboratory data. Forty-five patients were randomized to group A (n = 21) or B (n = 24). At 24 months, group A had significantly fewer contrast-enhanced lesions versus baseline (p = 0.007) and significantly fewer relapses versus the two pre-randomization years (p < 0.001). At survival analysis, the risk for a 1-point EDSS increase was slightly higher in group B than in group A (p = 0.053). Low-dose atorvastatin may be beneficial, as add-on therapy, in poor responders to high-dose interferon beta-1a alone.

More information

DOI

10.1177/1352458509358909

Type

Journal article

Publication Date

01/04/2010

Volume

16

Pages

450 - 454

Total pages

4

Addresses

Federico University, Neurological Sciences Department, Naples, Italy. robertalanzillo@libero.it

Keywords

Humans, Multiple Sclerosis, Relapsing-Remitting, Pyrroles, Heptanoic Acids, Interferon-beta, Anti-Inflammatory Agents, Contrast Media, Magnetic Resonance Imaging, Disability Evaluation, Treatment Outcome, Drug Therapy, Combination, Drug Administration Schedule, Severity of Illness Index, Chi-Square Distribution, Statistics, Nonparametric, Longitudinal Studies, Predictive Value of Tests, Time Factors, Adult, Female, Male, Interferon beta-1a, Atorvastatin